Boule Diagnostics AB (publ) (BOUL.ST)
SEK 8.84
(-1.56%)
SEK 8.84
(-1.56%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 57.7 Million SEK | -32.04% |
| 2022 | 84.89 Million SEK | 67.49% |
| 2021 | 50.69 Million SEK | 21.76% |
| 2020 | 41.63 Million SEK | -31.26% |
| 2019 | 60.56 Million SEK | 415.24% |
| 2018 | 11.75 Million SEK | -56.03% |
| 2017 | 26.73 Million SEK | -0.72% |
| 2016 | 26.92 Million SEK | 265.35% |
| 2015 | 7.37 Million SEK | -17.66% |
| 2014 | 8.95 Million SEK | 5.87% |
| 2013 | 8.45 Million SEK | 1079.22% |
| 2012 | 717 Thousand SEK | 16.02% |
| 2011 | 618 Thousand SEK | -91.04% |
| 2010 | 6.9 Million SEK | 1433.56% |
| 2009 | 450 Thousand SEK | 0.0% |
| 2008 | 450 Thousand SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 65.4 Million SEK | 13.26% |
| 2024 Q3 | 53.1 Million SEK | -16.51% |
| 2024 Q2 | 63.6 Million SEK | -2.75% |
| 2023 Q2 | 77.3 Million SEK | 0.39% |
| 2023 FY | 57.7 Million SEK | -32.04% |
| 2023 Q4 | 57.7 Million SEK | -6.79% |
| 2023 Q3 | 61.9 Million SEK | -19.92% |
| 2023 Q1 | 77 Million SEK | -9.3% |
| 2022 Q3 | 59.2 Million SEK | 29.54% |
| 2022 Q1 | 52.3 Million SEK | 3.18% |
| 2022 Q4 | 84.89 Million SEK | 43.41% |
| 2022 FY | 84.89 Million SEK | 67.49% |
| 2022 Q2 | 45.7 Million SEK | -12.62% |
| 2021 Q4 | 50.69 Million SEK | -4.54% |
| 2021 FY | 50.69 Million SEK | 21.76% |
| 2021 Q1 | 43 Million SEK | 3.29% |
| 2021 Q3 | 53.1 Million SEK | 29.2% |
| 2021 Q2 | 41.1 Million SEK | -4.42% |
| 2020 Q3 | 49.7 Million SEK | -28.59% |
| 2020 FY | 41.63 Million SEK | -31.26% |
| 2020 Q1 | 63.8 Million SEK | 5.35% |
| 2020 Q2 | 69.6 Million SEK | 9.09% |
| 2020 Q4 | 41.63 Million SEK | -16.24% |
| 2019 Q3 | 57 Million SEK | 8.16% |
| 2019 FY | 60.56 Million SEK | 415.24% |
| 2019 Q1 | 47.9 Million SEK | 307.52% |
| 2019 Q2 | 52.7 Million SEK | 10.02% |
| 2019 Q4 | 60.56 Million SEK | 6.25% |
| 2018 Q2 | 26.5 Million SEK | 12.77% |
| 2018 Q4 | 11.75 Million SEK | -5.21% |
| 2018 FY | 11.75 Million SEK | -56.03% |
| 2018 Q1 | 23.5 Million SEK | -12.09% |
| 2018 Q3 | 12.4 Million SEK | -53.21% |
| 2017 Q1 | 27.7 Million SEK | 2.87% |
| 2017 Q4 | 26.73 Million SEK | -4.86% |
| 2017 Q3 | 28.1 Million SEK | -3.44% |
| 2017 Q2 | 29.1 Million SEK | 5.05% |
| 2017 FY | 26.73 Million SEK | -0.72% |
| 2016 Q2 | 4.8 Million SEK | -9.43% |
| 2016 FY | 26.92 Million SEK | 265.35% |
| 2016 Q4 | 26.92 Million SEK | 17.58% |
| 2016 Q3 | 22.9 Million SEK | 377.08% |
| 2016 Q1 | 5.3 Million SEK | -28.09% |
| 2015 Q2 | 7.4 Million SEK | 0.0% |
| 2015 Q4 | 7.37 Million SEK | -6.71% |
| 2015 Q3 | 7.9 Million SEK | 6.76% |
| 2015 Q1 | 7.4 Million SEK | -17.33% |
| 2015 FY | 7.37 Million SEK | -17.66% |
| 2014 FY | 8.95 Million SEK | 5.87% |
| 2014 Q2 | 7.4 Million SEK | 0.0% |
| 2014 Q4 | 8.95 Million SEK | 14.76% |
| 2014 Q3 | 7.8 Million SEK | 5.41% |
| 2014 Q1 | 7.4 Million SEK | -12.48% |
| 2013 Q2 | 853 Thousand SEK | 19.13% |
| 2013 Q1 | 716 Thousand SEK | -0.14% |
| 2013 FY | 8.45 Million SEK | 1079.22% |
| 2013 Q4 | 8.45 Million SEK | 74.22% |
| 2013 Q3 | 4.85 Million SEK | 468.93% |
| 2012 Q2 | 8.74 Million SEK | 1315.21% |
| 2012 Q3 | 1.27 Million SEK | -85.39% |
| 2012 Q4 | 717 Thousand SEK | -43.9% |
| 2012 FY | 717 Thousand SEK | 16.02% |
| 2012 Q1 | 618 Thousand SEK | 0.0% |
| 2011 Q1 | 13.47 Million SEK | 95.28% |
| 2011 Q4 | 618 Thousand SEK | -94.02% |
| 2011 Q3 | 10.34 Million SEK | 59.62% |
| 2011 Q2 | 6.47 Million SEK | -51.93% |
| 2011 FY | 618 Thousand SEK | -91.04% |
| 2010 Q4 | 6.9 Million SEK | 0.0% |
| 2010 FY | 6.9 Million SEK | 1433.56% |
| 2009 FY | 450 Thousand SEK | 0.0% |
| 2008 FY | 450 Thousand SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 96.039% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 96.039% |
| Arcoma AB | 1.92 Million SEK | -2894.292% |
| Bactiguard Holding AB (publ) | 42.3 Million SEK | -36.387% |
| BICO Group AB (publ) | 1.75 Billion SEK | 96.713% |
| CellaVision AB (publ) | 28.66 Million SEK | -101.298% |
| Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | -25774.439% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.75 Million SEK | -3191.5% |
| Duearity AB (publ) | 2.94 Million SEK | -1862.585% |
| Dignitana AB (publ) | 6.07 Million SEK | -849.482% |
| Episurf Medical AB (publ) | 2.3 Million SEK | -2408.696% |
| Getinge AB (publ) | 3.9 Billion SEK | 98.522% |
| Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | -808.244% |
| Iconovo AB (publ) | 4.9 Million SEK | -1075.896% |
| Integrum AB (publ) | 4.84 Million SEK | -1091.029% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -27906.446% |
| Mentice AB (publ) | 2.14 Million SEK | -2591.231% |
| OssDsign AB (publ) | 214 Thousand SEK | -26862.617% |
| Paxman AB (publ) | 2.53 Million SEK | -2178.831% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 3 Million SEK | -1820.772% |
| SciBase Holding AB (publ) | 4.17 Million SEK | -1280.713% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 19.2 Million SEK | -200.458% |
| Sedana Medical AB (publ) | 1.01 Million SEK | -5601.581% |
| Senzime AB (publ) | 8.57 Million SEK | -572.651% |
| SpectraCure AB (publ) | 4.39 Million SEK | -1212.258% |
| Stille AB | 38.06 Million SEK | -51.579% |
| Vitrolife AB (publ) | 1.87 Billion SEK | 96.923% |
| Xvivo Perfusion AB (publ) | 21.16 Million SEK | -172.568% |